After Klinea’s sustained growth since its creation, it is now facing one of the most ambitious stages of expansion. The appointment of Marc Ramoneda has a double objective: to develop the European market and to create a new line of business related to BioPharma 4.0 technologies.
Marc has more than 20 years of experience developing the European market in the biopharmaceutical sector, where he started selling process equipment, engineering designs and turn-key projects; and, more recently, carrying out projects with an artificial intelligence platform for the optimisation of GxP manufacturing processes.
European expansion and the BioPharma 4.0 line of technologies are part of the new corporate strategy, to which is added a focus on biotechnology and environmental sustainability consulting.
In summary, the expansion of Klinea’s value proposition is centred on:
- The focus on biotechnology led by Jordi Gibert. Jordi has more than 15 years of experience in the biotechnology and biopharmaceutical sector, where he has been responsible for the development and scale-up of biological processes and has been head of production. He has recently focused his activity on the industrialisation of biological processes and the design of biopharmaceutical plants.
- The BioPharma 4.0 technology offer focuses on auditing the digital maturity level of the plant and proposing technological solutions focused on specific business cases.
- Sustainability consultancy focused on the SDGs (Sustainable Development Goals defined by the United Nations) related to reducing pollution and increasing energy efficiency.
The implementation of the new corporate strategy will be carried out gradually and consolidating stages to verify that the value proposition is solid and scalable.
At Klinea we are very proud of the road we have travelled and the whole team is looking forward to the challenges that await us.
